The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma

被引：19

作者：

Jiang, Han-yu ^{[1
]}

Zheng, Hui-min ^{[1
]}

Xia, Cheng ^{[1
]}

Li, Xiang ^{[1
]}

Wang, Gang ^{[1
]}

Zhao, Tong ^{[1
]}

Cui, Xiao-nan ^{[2
]}

Wang, Ruo-yu ^{[1
,3
]}

Liu, Ying ^{[1
,3
]}

机构：

[1] Dalian Univ, Affiliated Zhongshan Hosp, Dept Oncol, 6 Liberat St, Dalian 116001, Peoples R China

[2] Dalian Med Univ, Affiliated Hosp 1, Dept Oncol, Dalian 116011, Liaoning, Peoples R China

[3] Key Lab Biomarker High Throughput Screening & Tar, Dalian, Peoples R China

来源：

ONCOTARGETS AND THERAPY | 2022年 / 15卷

关键词：

bufalin; cancer; therapy; signaling pathways; immunotherapy effect; CANCER-CELLS; AUTOPHAGY; APOPTOSIS; PATHWAY; PROLIFERATION; HIF-1-ALPHA; SORAFENIB; MIGRATION; INVASION; KINASE;

D O I：

10.2147/OTT.S333233

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Hepatocellular carcinoma (HCC) is one of the deadliest cancers in the world with a five-year survival rate of less than 20%. Nonetheless, selecting an appropriate therapeutic agent to inhibit the development of hepatoma cells is still a challenge. Bufalin, a component of the traditional Chinese medicine Chansu, has been shown to inhibit the proliferation, invasion and metastasis of HCC through various signaling pathways. In addition, bufalin and sorafenib demonstrate a synergistic effect in cancer therapeutics. This review highlighted on several focal signaling pathways involved in the inhibitory effects of bufalin on HCC and its synergistic mechanisms with sorafenib. The immunotherapy effect of bufalin has also been discussed as a novel property.

引用

页码：291 / 298

页数：8

共 40 条

[1] Challenges in liver cancer and possible treatment approaches [J].

Anwanwan, David ;

Singh, Santosh Kumar ;

Singh, Shriti ;

Saikam, Varma ;

Singh, Rajesh .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1873 (01)

[2] A RETROVIRAL ONCOGENE, AKT, ENCODING A SERINE-THREONINE KINASE CONTAINING AN SH2-LIKE REGION [J].

BELLACOSA, A ;

TESTA, JR ;

STAAL, SP ;

TSICHLIS, PN .

SCIENCE, 1991, 254 (5029) :274-277

[3] Bufalin Inhibits Migration and Invasion in Human Hepatocellular Carcinoma SK-Hep1 Cells Through the Inhibitions of NF-kB and Matrix Metalloproteinase-2/-9-Signaling Pathways [J].

Chen, Ya-Yin ;

Lu, Hsu-Feng ;

Hsu, Shu-Chun ;

Kuo, Chao-Lin ;

Chang, Shu-Jen ;

Lin, Jen-Jyh ;

Wu, Ping-Ping ;

Liu, Jia-You ;

Lee, Ching-Hsiao ;

Chung, Jing-Gung ;

Chang, Jin-Biou .

ENVIRONMENTAL TOXICOLOGY, 2015, 30 (01) :74-82

[4] Extracellular polyamines-induced proliferation and migration of cancer cells by ODC, SSAT, and Akt1-mediated pathway [J].

Dai, Fujun ;

Yu, Wubei ;

Song, Jia ;

Li, Qian ;

Wang, Chaojie ;

Xie, Songqiang .

ANTI-CANCER DRUGS, 2017, 28 (04) :457-464

[5] Life and death partners: apoptosis, autophagy and the cross-talk between them [J].

Eisenberg-Lerner, A. ;

Bialik, S. ;

Simon, H-U ;

Kimchi, A. .

CELL DEATH AND DIFFERENTIATION, 2009, 16 (07) :966-975

[6] Bufalin Suppresses Migration and Invasion of Hepatocellular Carcinoma Cells Elicited by Poly (I:C) Therapy [J].

Feng, Yinglu ;

Chen, Yongan ;

Meng, Yongbin ;

Cao, Qingxin ;

Liu, Qun ;

Ling, Changquan ;

Wang, Chen .

ONCOIMMUNOLOGY, 2018, 7 (05)

[7] The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway [J].

Gai, Ji Qin ;

Sheng, Xia ;

Qin, Jian Min ;

Sun, Kang ;

Zhao, Wei ;

Ni, Lei .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (01) :338-348

[8] Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK [J].

Gao, Yang ;

Li, Hua-Xing ;

Xu, Li-Tao ;

Wang, Peng ;

Xu, Li-Yan ;

Cohen, Lorenzo ;

Yang, Pei-Ying ;

Gu, Ke ;

Meng, Zhi-Qiang .

MOLECULAR BIOLOGY REPORTS, 2012, 39 (02) :1683-1689

[9]

Goto M, 2008, BIOSCI TRENDS, V2, P124

[10]

Hong L, 2021, J GUANGDONG MED U, V39, P2

← 1 2 3 4 →